An observational study in Shoulder Pain, Shoulder Injuries and Shoulder Arthritis, sponsored by International Spine, Pain and Performance Center. Completed at 2 sites in United States. Open to participants aged 21 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by International Spine, Pain and Performance Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.
Among the 146 studies in Shoulder Pain with a site in United States, this one is the 24th largest by enrollment of the 24 observational ones that give a count, is one of 9 that started in 2022, is one of 24 observational ones, and was the 123rd registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–45 · Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Prisma Health-Upstate · Sites in United States
Ages 21–65 · Women only
Lisa Griffin · Sites in United States
Ages 60+
University of Florida · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 21 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 21
First in 2003; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 84 across 135 observational studies indexed under Shoulder Pain.
Median enrollment 50 across the 122 interventional studies, 65 across the 24 observational. Of the 101 that completed or were terminated, 32 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 146 have an industry lead sponsor. The 10 most frequent:
International Spine, Pain and Performance Center is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
International Spine, Pain and Performance Center has 1 study filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
12 of the studies in Shoulder Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851233Rothman Institute OrthopaedicsPatient Education and Sling Use After Shoulder Surgery | 2026-11-30 |
| NCT06039345University of UtahShoulder RFA Pilot Study | 2026-12 |
| NCT07101250Prisma Health-UpstatePreoperative Acetazolamide | 2026-12-01 |
| NCT03653455Rush University Medical CenterPatient Outcomes Collection: How Can we do Better? | 2026-12-31 |
| NCT07400146Cedars-Sinai Medical CenterBupivacaine With Epinephrine Over Diaphragm in Laparoscopy | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 146 studies in Shoulder Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to gather post-market data regarding the effectiveness of the SPRINT Peripheral Nerve Stimulation (PNS) System for the treatment of chronic shoulder pain due to chronic degenerative changes of your shoulder. The System delivers mild electrical stimulation to the muscles in your shoulder. The System includes up to two leads (small wires) that are placed through your skin into your shoulder. The leads attach to a device worn on your body that deliver stimulation (called a Stimulator). The device is cleared by the FDA for up to 60 days of use for the relief of chronic or acute pain.
Background
Chronic degenerative changes in the shoulder are a frequent source of debilitating chronic pain. In particular, osteoarthritis of the shoulder has been estimated to affect up to 32.8% of the adult population over the age of 60, and OA in general is one of the most frequent causes of disability in the United States.1 OA impacts the quality of life of tens of millions of Americans and carries a significant economic burden of over $60 billion in the U.S. each year.2
Degenerative joint disease in the shoulder is commonly managed with physical therapy and over-the-counter medications, but these modalities can be insufficient for pain management as degeneration progresses.3 Corticosteroid injections, radiofrequency ablations, and even partial or total shoulder arthroplasty are used to treat advanced cases3, and these interventions often either have limited long-term effectiveness or are associated with significant invasiveness or other side effects and complications.
Peripheral nerve stimulation (PNS) is a neuromodulatory technique that seeks to provide pain relief through stimulation of the nerves that innervate the shoulder (e.g., the suprascapular nerve and axillary nerve). A novel, 60-day percutaneous PNS system that is FDA-cleared has shown effectiveness for chronic shoulder pain following stroke and shoulder impingement syndrome4-15, and has demonstrated the potential to provide sustained relief following the short-term, 60-day treatment.8, 15-18 The mechanism of action of neuropathic pain in osteoarthritis is proposed to be via peripheral sensitization (e.g., axillary and suprascapular nerves) that leads to subsequent upstream hypersensitization of the central nervous system; the proposed mechanism of long-term pain relief with 60-day PNS via reconditioning of the CNS to reverse hypersensitization therefore suggests that the treatment may be effective for degenerative shoulder including OA.19, 20 However, no study has prospectively evaluated the use of 60-day, percutaneous PNS for the treatment of debilitating pain associated with degenerative changes in the shoulder. The goal of this study is therefore to collect data on the use of 60-day PNS for the treatment of chronic pain associated with degenerative shoulder.
Objectives
The study objective is to gather post-market data regarding the effectiveness of the SPRINT PNS System for the treatment of chronic shoulder pain due to degenerative changes of the shoulder.
The study will enroll up to 20 patients with pain due to degenerative changes in the shoulder scheduled for commercial placement of the SPRINT PNS System.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Number of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain Intensity
All subjects completed PROMIS-29 Profile v.21 and BPI-9 at Baseline and at 3-months after the start of treatment. Average pain intensity is measured using the Brief Pain Inventory--Short form Question #9 (BPI-9). BPI-9 uses a 0-10 numeric rating scale across seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance). Average pain interference was calculated utilizing PROMIS-29. The average score for the PROMIS-29 pain interference assessment for the general population in the United States is 50, with a standard deviation of 10. The raw score for pain interference ranges from 4 to 20. Higher scores on PROMIS measures indicated more of the concept being measured. For example, a score of 60 is one standard deviation above the average population.
Time frame: 3 months
Percent Change in Pain Interference Score
Changes in average pain interference are measured using PROMIS-29 v2.1, Pain Interference domain. This domain includes four questions intended to capture a patient's ability to function in daily life living with pain. Questions assess pain interference with: day to day activities, work around the home, social activities, and household chores. Patients report the degree of pain interference via five-point Likert scale, from "Not at all" to "Very much." A positive change would indicate an increase in pain interference in activities of daily living from baseline, while a negative change would indicate a decrease in pain interference.
Time frame: 3 months
Changes in Shoulder Function
Shoulder function is measured using the Western Ontario Arthritis of the Shoulder (WOOS) index. The WOOS index is a patient-reported, disease-specific questionnaire for the measurement of the quality-of-life in patients with osteoarthritis.
Time frame: 1 year
Changes in Shoulder Range of Motion
Shoulder range of motion is measured as degrees of active range of motion (flexion, abduction, internal rotation, and external rotation) based on physical examination.
Time frame: 1 year
Participants were recruited who received the SPR PNS device commercially at our pain practice between June 2022 and June 2024. The first participant was enrolled on July 12, 2022 and the final participant was enrolled on September 27, 2023.
| Milestone | SPR PNS |
|---|---|
| Started | 2 |
| Completed | 1 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
All subjects completed PROMIS-29 Profile v.21 and BPI-9 at Baseline and at 3-months after the start of treatment. Average pain intensity is measured using the Brief Pain Inventory--Short form Question #9 (BPI-9). BPI-9 uses a 0-10 numeric rating scale across seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance). Average pain interference was calculated utilizing PROMIS-29. The average score for the PROMIS-29 pain interference assessment for the general population in the United States is 50, with a standard deviation of 10. The raw score for pain interference ranges from 4 to 20. Higher scores on PROMIS measures indicated more of the concept being measured. For example, a score of 60 is one standard deviation above the average population.
| Participants | SPR PNS |
|---|---|
| Number of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain Intensity | 1 |
Changes in average pain interference are measured using PROMIS-29 v2.1, Pain Interference domain. This domain includes four questions intended to capture a patient's ability to function in daily life living with pain. Questions assess pain interference with: day to day activities, work around the home, social activities, and household chores. Patients report the degree of pain interference via five-point Likert scale, from "Not at all" to "Very much." A positive change would indicate an increase in pain interference in activities of daily living from baseline, while a negative change would indicate a decrease in pain interference.
| percent change | SPR PNS |
|---|---|
| Percent Change in Pain Interference Score | -18.4 (-26.3 to -10.5) |
Shoulder function is measured using the Western Ontario Arthritis of the Shoulder (WOOS) index. The WOOS index is a patient-reported, disease-specific questionnaire for the measurement of the quality-of-life in patients with osteoarthritis.
Results for this outcome have not been posted.
Shoulder range of motion is measured as degrees of active range of motion (flexion, abduction, internal rotation, and external rotation) based on physical examination.
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPR PNS | — | — | — |
Subjects who consented and received the SPR PNS device for chronic shoulder pain.
| Age, Continuous(years) | SPR PNS |
|---|---|
| Mean | 83.5 (78 to 89) |
| Sex: Female, Male(Participants) | SPR PNS |
|---|---|
| Female | 2 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | SPR PNS |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 2 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | SPR PNS |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Current Employment Status(Participants) | SPR PNS |
|---|---|
| Retired (not due to health) | 2 |
| Currently Working | 0 |
| On leave of absence | 0 |
| Homemaker | 0 |
| Unemployed | 0 |
| Student | 0 |
| Disabled and/or retired because of pain | 0 |
| Tobaco History(Participants) | SPR PNS |
|---|---|
| Never Smoked | 2 |
| Past Smoker | 0 |
| Current Smoker | 0 |
Plan to share: Undecided
Ran from Jul 2022 to primary completion in Jun 2024, 22 months.
Results were first posted in Nov 2026, 2 years 5 months after primary completion.
Of 49 non-industry observational studies under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 24. This study's 22 months is above that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 35.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2024 → Jun 2024, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Spine, Pain and Performance Center